TG Therapeutics, Inc. (TGTX) Financials

TGTX Assets vs Liabilities

DateAssetsLiabilities
2023-12-31 329.6 million 169.1 million
2023-09-30 331.1 million 166.3 million
2023-06-30 220.9 million 180.4 million
2023-03-31 197.4 million 169.9 million

TGTX Free Cash Flow and Stock based compensation

Graph available only for supporters. Become a supporter to see it.
DateFree Cash FlowStock based compensation
2023-12-31 -13.2 million 9.4 million
2023-09-30 83.7 million 9.2 million
2023-06-30 -42.0 million 12.5 million
2023-03-31 -59.9 million 6.8 million

TGTX Net Income

No data available :(

TGTX Cash and Debt

Graph available only for supporters. Become a supporter to see it.
DateCashDebtCapital Lease
2023-12-31 217.5 million - 10.7 million
2023-09-30 229.2 million - 11.0 million
2023-06-30 144.9 million 97.7 million 11.3 million
2023-03-31 139.7 million 96.5 million 11.6 million

TGTX Shares Outstanding

Graph available only for supporters. Become a supporter to see it.
DateShares Outstanding
2023-12-31 143.1 million
2023-09-30 155.9 million
2023-06-30 141.5 million
2023-03-31 140.3 million

TGTX Expenses

Graph available only for supporters. Become a supporter to see it.
DateCapexR&DG&AS&M
2023-12-31 - 17.4 million 34.0 million -2.9 million
2023-09-30 - 11.8 million 35.7 million -9.2 million
2023-06-30 - 22.5 million 36.4 million -
2023-03-31 - 14.3 million 29.7 million -

TGTX Cost of Revenue

Graph available only for supporters. Become a supporter to see it.
DateRevenueCost of Revenue
2023-12-31 44.0 million 7.9 million
2023-09-30 165.8 million 3.5 million
2023-06-30 16.1 million 1.9 million
2023-03-31 7.8 million 857000

TGTX

Price: $16.52

52 week price:
6.46
35.67

Earnings Per Share: 0.09 USD

P/E Ratio: -80.79

Exchange: NCM

Sector: Healthcare

Industry: Biotechnology

Volume: 2.7 million

Ebitda: -31.6 million

Market Capitalization: 2.3 billion

Links: